Categories
Health Alert

Foods May Contribute to Infertility

[amazon_link asins=’B00HKIBKQS,B00AO7I15A,B00MFRARWC,1617691577,B00D3S39PE,B00426ATTK’ template=’ProductCarousel’ store=’finmeacur-20′ marketplace=’US’ link_id=’f5f549da-d44e-11e7-aaa7-13d58b21ee1f’]

Millions of people have celiac disease, but most don’t know they have it, in part because symptoms can be so varied. It is an often overlooked digestive disorder that causes damage to the small intestine when gluten, a protein found in wheat, barley and rye, is eaten.
………….

People sensitive to the gluten in bread, pasta and other foods may face fertility problems.

Infertility seems to be more common in women with untreated celiac disease. Other gynecological and obstetrical problems may also be more common, including miscarriages and preterm births.

For men, problems can include abnormal sperm — such as lower sperm numbers, altered shape, and reduced function. Men with untreated celiac disease may also have lower testosterone levels.

The good news is that with proper treatment with a gluten-free diet and correction of nutritional deficiencies, the prognosis for future pregnancies is much improved.

Source: New York Times February 3, 2010

Reblog this post [with Zemanta]
Categories
Health Alert

Sharing Your Bed May be Bad for Your Health

 

Couples should consider sleeping apart for the good of their health and relationship, say experts.

One study found that, on average, couples suffered 50 percent more sleep disturbances if they shared a bed.

The modern tradition of the marital bed only began with the industrial revolution, when people moving to overcrowded towns and cities found themselves short of living space. Before the Victorian era it was not uncommon for married couples to sleep apart.

Source: BBC News , January 26, 2010

Reblog this post [with Zemanta]
Categories
Health Alert

Stub That Butt Out

Pharmaceutical companies play up the use of anti-tobacco aids, which makes quitting smoking without help seem impossible……….. But it’s not, T.V. Jayan points out
…..….
Are the global efforts to kick the butt dimmed by distortion and deception? Perhaps, says tobacco control expert Simon Chapman.

A public health researcher at the University of Sydney, Chapman — who wrote more than a dozen tomes on tobacco control — has unearthed a disturbing trend in smoking cessation attempts. The pharmaceutical industry has been trying to create the false impression that attempting to quit smoking without medicines or nicotine replacement therapy (NRT) is futile, reveal Chapman and his colleague Ross McKenzie. Their article appeared in the journal PLoS Medicine last week.

With the industry proclaiming that “willpower alone is not enough to quit”, smokers may think it’s useless to try to kick the habit without any aid, they say.

“The aim should be to encourage attempts to quit smoking, and not constantly describe it as difficult. The process has become overly medicalised for many,” Chapman told KnowHOW.

Not surprisingly, nearly two-third to three-quarters of those who quit smoking did so without any professional or therapeutic help, he adds. This, even though anti-tobacco drugs — such as bupropion and varenicline — and NRT products like patches, gum and lozenges have been in the market for more than 25 years.

NRT, medicines and professional counselling or support may help many smokers, but are not necessary for quitting, asserts Chapman.

According to experts, the cold-turkey method — where you progressively reduce the number of cigarettes before stopping completely — is still the most preferred approach. And campaigners are pleased that in a growing number of countries, there are now more non-smokers than smokers.

Chapman and McKenzie, who analysed more than 660 papers on smoking cessation published in 2007 and 2008, found that the industry and many tobacco control researchers have conveniently neglected the power of unaided cessation. On the other hand, there has been an attempt to play up the benefits of pharmacological intervention.

The study also brought to light a bias in research on assisted cessation. While industry-supported research showed that quit-smoking medicines and NRT products have a 51 per cent efficiency, independent studies said the impact was just 22 per cent.

“Because of these attitudes, smoking cessation is becoming increasingly pathologised, a development that risks distorting public awareness of how most smokers quit, to the obvious benefit of the pharmaceutical companies,” say the researchers.

The study comes at a good time, when India is embarking on a major tobacco control campaign. In the last week of January, the Union cabinet approved a Rs 182-crore tobacco control programme. The project — which would cover 42 districts in 21 states — is expected to step up public awareness of the ill effects of tobacco use by setting up testing labs and conducting adult tobacco surveys over the next two years.

Sadly, India has one of the poorest rates of quitting: only about 2 per cent of the smoking population is able to kick the habit annually.

Chapman’s views are echoed by Prakash Chopra, a tobacco control expert and director of the Healis-Sekhsaria Institute of Public Health, Mumbai. Chopra strongly believes that there is a need to publicise the fact that most smokers quit without any aid.

“It isn’t enough for public health policymakers to simply stress this fact; they must also assist unassisted cessation,” he says. This can be done by allocating funds for initiating and enforcing policies in this direction, he suggests.

Chapman points out that most of the government money for tobacco control is spent in support of NRT or similar strategies rather than in aiding unassisted cessation. The criticism seems more than valid, as within a couple of days of publishing his paper many experts from all over the world came up with similar views.

Prabhat Jha, director of the Centre for Global Health Research in Canada, however, believes that pharmaceutical aids do help, though only for a brief while. “These aids double the effectiveness of smoking cessation attempts from a quit rate of about 3 per cent to up to 8 per cent in the following six months. It is true that a vast number of quitters quit cold turkey. But pharmaceutical drugs do help, and if they help more smokers to quit, it’s a good thing,” says Jha.

According to Jha, there is another way out of the haze — tobacco products should be taxed higher. In developing countries, a 10 per cent higher price, it has been found, results in about 3 to 4 per cent of smokers quitting, and another 3 to 4 per cent of individuals not taking up the habit, he says.

Higher prices and then drugs and therapy — why not use your willpower and save your health as well as money?

Source: The Telegraph (Kolkata) India

Reblog this post [with Zemanta]
Categories
Chemicals & Minerals Health Alert News on Health & Science

Present Position of FDA About BPA Risks

[amazon_link asins=’B00V6LXOWI,B076D359KQ’ template=’ProductCarousel’ store=’finmeacur-20′ marketplace=’US’ link_id=’790ded7d-c446-11e7-843f-0146f4b8b8d6′]

In a shift of position, the U.S. FDA is expressing concerns about possible health risks from bisphenol A, or BPA, a widely used component of plastic bottles and food packaging. The agency declared BPA safe in 2008.

………………..

But the FDA now has “some concern about the potential effects of BPA on the brain, behavior and prostate gland of fetuses, infants and children.”

The action is another example of the drug agency becoming far more aggressive in taking hard looks at what it sees as threats to public health over the past year. In recent months, the agency has stepped up its oversight of food safety and has promised to tighten approval standards for medical devices.

Concerns about BPA are based on studies that have found harmful effects in animals, and on the recognition that the chemical seeps into food and baby formula. Nearly everyone is exposed to BPA, starting in the womb.

Dr. Sharfstein said the drug agency was also re-evaluating the way it regulates BPA.

The substance is now classified as a food additive, a category that requires a cumbersome and time-consuming process to make regulatory changes. Dr. Sharfstein said he hoped its status could be changed to “food contact substance,” which would give the F.D.A. more regulatory power and let it act more quickly if it needed to do so.

Resources:
New York Times January 15, 2010
New York Times FDA Articles
New York Times May 14, 2009

Reblog this post [with Zemanta]
Categories
Health Alert

Warning! Don’t Take Another Drug Until You Read How You’re Being Conned…

Osteoporosis is a disease that causes bones to become thinner, more porous and break more easily. Osteopenia is different from osteoporosis — it is a slight thinning of bones that occurs naturally as women get older and typically doesn’t result in disabling bone breaks.


Osteopenia is a condition that only recently started to be thought of as a problem that required treatment. Until the early 1990’s, only a handful of people had even heard of the word. But osteopenia has transformed from a rarely heard word into a problem that millions of women swallow pills to treat.

The term “osteopenia” was never originally meant to be considered as a disease — it was a research category used mostly because some thought it might be useful for public health researchers who like clear categories for their studies.

But in 1995, a man named Jeremy Allen was approached by the drug company Merck. The pharmaceutical giant had just released a new osteoporosis drug called Fosamax. Since osteoporosis is a serious problem that affects millions of women, the potential market for Fosamax was enormous. But the drug wasn’t selling well.

Allen persuaded Merck to establish a nonprofit called the Bone Measurement Institute. On its board were six of the most respected osteoporosis researchers in the country.

But the institute itself had a rather slim staff: Allen was the only employee.

In 1997 the institute and several other interested organizations successfully lobbied to pass the Bone Mass Measurement Act, a piece of legislation that changed Medicare reimbursement rules to cover bone scans. More and more women got bone density tests (at Merck’s urging), and the very existence of the word “osteopenia” on a medical report had a profound effect.

Millions of women were worried by the diagnosis. And when clinicians saw the word ‘osteopenia’ on a report, they assumed it was a disease. Merck did not disabuse them of the notion.

There are no long-term studies that look at what happens to women with osteopenia who start Fosamax in their 50’s and continue treatment long-term in the hopes of preventing old-age fractures. And none are planned.

Resources:
WHO FRAX
NPR December 21, 2009
NPR 2009 (Sample Radiology Report)

Reblog this post [with Zemanta]
css.php